Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study

PLoS Medicine

Volumn 13, Issue 12, 2016, Pages

  Kridel, Robert ^a,i   Chan, Fong Chun ^a,b   Mottok, Anja ^a,b   Boyle, Merrill ^a   Farinha, Pedro ^a   Tan, King ^a   Meissner, Barbara ^a   Bashashati, Ali ^a   McPherson, Andrew ^a   Roth, Andrew ^a,b   Shumansky, Karey ^a   Yap, Damian ^a   Ben Neriah, Susana ^a   Rosner, Jamie ^a   Smith, Maia A ^a,b   Nielsen, Cydney ^a   Giné, Eva ^a   Telenius, Adele ^a   Ennishi, Daisuke ^a   Mungall, Andrew ^a   Moore, Richard ^a   Morin, Ryan D ^a,c   Johnson, Nathalie A ^d   Sehn, Laurie H ^a   Tousseyn, Thomas ^e,f   Dogan, Ahmet ^g,h   Connors, Joseph M ^a   Scott, David W ^a   Steidl, Christian ^a,b   Marra, Marco A ^a   Gascoyne, Randy D ^a,b   Shah, Sohrab P ^a,b   more..

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g MAYO CLINIC   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPLICON; ARTICLE; BIOINFORMATICS; CANCER GROWTH; CANCER PROGNOSIS; CELL TRANSFORMATION; CLONAL EVOLUTION; COHORT ANALYSIS; COPY NUMBER VARIATION; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; GENE; GENE MUTATION; GENOME ANALYSIS; INDEL MUTATION; PHYLOGENY; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; CELL CLONE; DISEASE COURSE; GENETICS; HUMAN; MUTATION; PATHOPHYSIOLOGY;

CLONAL EVOLUTION; CLONE CELLS; DISEASE PROGRESSION; HUMANS; LYMPHOMA, FOLLICULAR; MUTATION;

EID: 85007524268     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002197     Document Type: Article

References (43)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89(11):3909–18. 9166827
2. Anderson JR, Armitage JO, Weisenburger DD, Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998;9(7):717–20. 9739436
3. Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K, et al. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica. 2013;98(7):1107–14. doi: 10.3324/haematol.2012.08241223645690
4. Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, et al. Improvements in observed and relative survival in follicular grade 1–2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981–7. doi: 10.1182/blood-2013-03-49151423777769
5. Junlen HR, Peterson S, Kimby E, Lockmer S, Linden O, Nilsson-Ehle H, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women—a Swedish Lymphoma Registry study. Leukemia. 2014;29(3):668–76. doi: 10.1038/leu.2014.25125151959
6. Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25(17):2426–33. doi: 10.1200/JCO.2006.09.326017485708
7. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26(32):5165–9. doi: 10.1200/JCO.2008.16.028318838711
8. Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31(26):3272–8. doi: 10.1200/JCO.2012.48.399023897955
9. Mozessohn L, Cheung MC, Crump M, Buckstein R, Berinstein N, Imrie K, et al. Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis. Leuk Lymphoma. 2014;55(11):2502–7. doi: 10.3109/10428194.2014.88551324450580
10. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516–22. doi: 10.1200/JCO.2014.59.753426124482
11. Lerch K, Meyer AH, Stroux A, Hirt C, Keller U, Viardot A, et al. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis. Ann Hematol. 2015;94(6):981–8. doi: 10.1007/s00277-015-2303-525645656
12. Wagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015;126(7):851–8. doi: 10.1182/blood-2015-01-62137526105149
13. Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128(8):1112–20. doi: 10.1182/blood-2016-05-71735527418643
14. Ding L, Ley TJ, Larson DE, Miller Ca, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506–10. doi: 10.1038/nature1073822237025
15. Da Landau, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714–26. doi: 10.1016/j.cell.2013.01.01923415222
16. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525–30. doi: 10.1038/nature1539526466571
17. Morrissy AS, Garzia L, Shih DJH, Zuyderduyn S, Huang X, Skowron P, et al. Divergent clonal selection dominates medulloblastoma at recurrence. Nature. 2016;529(7586):351–7. doi: 10.1038/nature1647826760213
18. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366(12):1090–8. doi: 10.1056/NEJMoa110696822417201
19. Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, Mullighan CG, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013;210(11):2273–88. doi: 10.1084/jem.2013144824127483
20. Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46(2):176–81. doi: 10.1038/ng.285624362818
21. Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes A, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6(1):130–40. doi: 10.1016/j.celrep.2013.12.02724388756
22. Yano T, Jaffe ES, Longo DL, Raffeld M, MYC rearrangements in histologically progressed follicular lymphomas. Blood. 1992;80(3):758–67. 1638027
23. Lossos IS, Alizadeh AA, Diehn M, Warnke R, Thorstenson Y, Oefner PJ, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A. 2002;99(13):8886–91. doi: 10.1073/pnas.13225359912077300
24. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R, p53 mutations are associated with histologic transformation of follicular lymphoma. Blood. 1993;82(8):2289–95. 8400281
25. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 1993;82(7):1994–2004. 8400252
26. Fitzgibbon J, Iqbal S, Davies A, O’Shea D, Carlotti E, Chaplin T, et al. Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia. 2007;21(7):1514–20. doi: 10.1038/sj.leu.240469617495976
27. Davies AJ, Rosenwald A, Wright G, Lee A, Last KW, Weisenburger DD, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol. 2007;136(2):286–93. doi: 10.1111/j.1365-2141.2006.06439.x17278262
28. Carlotti E, Wrench D, Matthews J, Iqbal S, Davies A, Norton A, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood. 2009;113(15):3553–7. doi: 10.1182/blood-2008-08-17483919202129
29. O’Shea D, O’Riain C, Gupta M, Waters R, Yang Y, Wrench D, et al. Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood. 2009;113(10):2298–301. doi: 10.1182/blood-2008-08-17495319141865
30. Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Arnesen M, Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med. 1987;316(2):79–84. doi: 10.1056/NEJM1987010831602043537802
31. Tilly H, Rossi A, Stamatoullas A, Lenormand B, Bigorgne C, Kunlin a, et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood. 1994;84(4):1043–9. 8049424
32. Höglund M, Sehn L, Connors JM, Gascoyne RD, Siebert R, Säll T, et al. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer. 2004;39(3):195–204. doi: 10.1002/gcc.1031414732921
33. O’Shea D, O’Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood. 2008;112(8):3126–9. doi: 10.1182/blood-2008-05-15401318628487
34. D’Amore F, Chan E, Iqbal J, Geng H, Young K, Xiao L, et al. Clonal evolution in t(14;18)-positive follicular lymphoma, evidence for multiple common pathways, and frequent parallel clonal evolution. Clin Cancer Res. 2008;14(22):7180–7. doi: 10.1158/1078-0432.CCR-08-075219010834
35. Cheung KJJ, Shah SP, Steidl C, Johnson N, Relander T, Telenius A, et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood. 2009;113(1):137–48. doi: 10.1182/blood-2008-02-14061618703704
36. Alhejaily A, Day AG, Feilotter HE, Baetz TD, Lebrun DP, Inactivation of the CDKN2A tumor suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome. Clin Cancer Res. 2014;20(6):1676–86. doi: 10.1158/1078-0432.CCR-13-217524449825
37. Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;2045(15):1–12.
38. Roth A, Khattra J, Yap D, Wan A, Laks E, Biele J, et al. PyClone: statistical inference of clonal population structure in cancer. Nat Methods. 2014;11(4):396–8. doi: 10.1038/nmeth.288324633410
39. Malikic S, McPherson AW, Donmez N, Sahinalp CS, Clonality inference in multiple tumor samples using phylogeny. Bioinformatics. 2015;31(9):1349–56. doi: 10.1093/bioinformatics/btv00325568283
40. Muppidi JR, Schmitz R, Green JA, Xiao W, Larsen AB, Braun SE, et al. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma. Nature. 2014;516(7530):254–8. doi: 10.1038/nature1376525274307
41. Schiffels S, Szöllosi GJ, Mustonen V, Lässig M, Emergent neutrality in adaptive asexual evolution. Genetics. 2011;189(4):1361–75. doi: 10.1534/genetics.111.13202721926305
42. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–52. doi: 10.1038/nature1098322522925
43. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O’Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–77. doi: 10.1182/blood-2010-05-28278020628145